GLP‑1 use is messy

Glucagon-like peptide 1 drugs are built for long-term treatment, but many people who start them stop within a year and say they expect to go back. (ijpr.org) These medicines copy gut hormones that curb appetite and help control blood sugar. Brand names include Ozempic and Mounjaro for type 2 diabetes, and Wegovy and Zepbound for obesity treatment. (webmd.com) A 2025 analysis of 125,474 U.S. adults found that within one year, 46.5% of patients with type 2 diabetes and 64.8% without diabetes had discontinued a glucagon-like peptide 1 drug. Within two years, those rates rose to 64.1% and 84.4%. (medicalxpress.com) The same analysis found that among patients who stopped and had a weight measurement, 47.3% of those with diabetes and 36.3% without diabetes restarted within a year. Gastrointestinal side effects, weight regain, cost, and access all showed up in the stop-and-restart pattern. (medicalxpress.com) Leigh O'Donnell of the market research firm Kantar told National Public Radio that 74% of people who had lapsed on a glucagon-like peptide 1 drug said they were likely or very likely to return. Doctors told the outlet that cycling on and off treatment is common, but the health effects of repeated stopping and restarting are still unclear. (ijpr.org) Researchers have stronger evidence on what happens after stopping once than on repeated cycling. A November 2024 Journal of the American Medical Association commentary said randomized trials showed rapid weight regain and worsening cardiometabolic measures after semaglutide or tirzepatide was discontinued. (jamanetwork.com) A March 12, 2026 Cleveland Clinic analysis of 7,938 adults offered a messier real-world picture. It found 45% of patients treated for obesity kept losing weight or stayed weight-stable a year after stopping, while many others restarted the same drug or switched to another obesity treatment. (newsroom.clevelandclinic.org) Money is a major reason people stop. KFF said on March 24, 2026 that 56% of users reported these drugs were difficult to afford, and current law still generally bars Medicare from covering obesity drugs when prescribed specifically for weight loss. (kff.org) The drugs also require step-up dosing, which makes restarting less simple than picking up where someone left off. The Food and Drug Administration label for Zepbound says treatment starts at 2.5 milligrams once a week for four weeks before moving up in 2.5 milligram steps. (accessdata.fda.gov) Use is now broad enough that these stop-and-start patterns affect a large patient pool. KFF reported in May 2024 that 12% of U.S. adults said they had ever taken a glucagon-like peptide 1 drug, including 6% who said they were taking one at the time. (kff.org) For now, the basic split is straightforward: the drugs are meant to be chronic treatment, but real life keeps interrupting them. The result is a growing group of patients treating obesity and diabetes in bursts while researchers are still trying to measure what those interruptions do. (jamanetwork.com)